Figure 2.
Effect of fezolinetant on VMSs over time. (A) Daily total VMS score during week 4 and week 12. (B) Frequency of moderate/severe VMSs during the duration of the study. (C) Moderate/severe VMS score during the duration of the study. Data are presented as mean ± 95% CI (mITT population, observed data).

Effect of fezolinetant on VMSs over time. (A) Daily total VMS score during week 4 and week 12. (B) Frequency of moderate/severe VMSs during the duration of the study. (C) Moderate/severe VMS score during the duration of the study. Data are presented as mean ± 95% CI (mITT population, observed data).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close